This article is more than 5 years old. Information may no longer be current.

Inflammatory mediators may signal risk of active ocular Behçet disease

Eur J Ophthalmol. 2009;19(6):999-1004.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Serum levels of inflammatory mediators may indicate which patients are at risk for active ocular involvement of Behçet disease.

According to a prospective clinical trial of 43 patients with known ocular Behçet disease, levels of interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-alpha), VEGF and malondialdehyde (MDA) were all found to be significantly higher in patients with active manifestations of Behçet disease (Group A) compared with patients with inactive Behçet disease (Group B).

Active disease was characterized by posterior uveitis, either vitritis or chorioretinal involvement.

According to the study, "serum levels of the mediators in Group A (IL-6 [23.1 pg/mL], IL-8 [161.1 pg/mL], TNF-alpha [30.5 pg/mL], VEGF [455.9 pg/mL], MDA [10.7 µm]) were found to be significantly higher than those in Group B (IL-6 [12.2 pg/mL], IL-8 [48.4 pg/mL], TNF-alpha [18.6 pg/mL], VEGF [138.0 pg/mL], MDA [5.1 µm])."